FDA Investigator Barbara J Wilimczyk

Barbara J Wilimczyk has inspections in 2 countries as of 03 Nov 2023. Barbara J Wilimczyk has collaborated with a combinined 1853 experts on various inspections, contributing to compliance and improvement across diverse sectors.

Investigator Details

Number of Inspected Sites:
19
Last Inspection Date:
03 Nov 2023
Investigator Role:
FDA Investigation Participant
Redica ID:
100006400
Country:
United States of America
Co-Investigator(s):
Addam S Reynolds, Adetutu M Gidado, Amy L Singer, Amy M Codella, Amy M Cramer, Ankur C Patel, Annemarie Bodnar, Atul J Agrawal, Barbara J Maulfair, Barbara Jwilimczyk Macri, Christine M Cerenzio, Cory Greene, Craig W Swanson, Daniel J Grabicki, David A Oluwo, Dawn L Wydner, Deborah B Nixon, Devon Jenkins, Dhaval H Patel, Douglas C Kovacs, Dr. Gang Wang, PhD, Dr. Robert C Horan, MD, Emest F Bizjak, Emmanuel J Ramos, Emmanuel Jramos Maldonado, Eric Rothschild, Erin D Mccaffery, Fred Razzaghi, Frederick Razzaghi, George Pyramides, Gianine E Tompkins, Guerlain Ulysse, Helen B Ricalde, Helen Verdel, Jogy George, Jonathan G Matrisciano, Jose M Cayuela, Joseph F Mcginnis, RPh, Joseph Mcginnis, Joy Rkozlowski Klena, Junho Pak, Justine Tomasso, Karen E D'orazio, Keith Wonnacott, PhD, Kelli F Dobilas, Kelli Regente, Ko U Min, Kristen E Rescigno, Kristy A Zielny, Krystyna M Kitson, Laura Fontan, MS, Lauren L Vajo, Li Li, Liatte Kreuger, PharmD, Lisa M Bellows, Loretta Nemchik, Marcelo O Mangalindan, Jr, Marea K Harmon, Margaret M Sands, Maria Estrella, Mary P Padgett, Matthew A Spataro, Melba T Rivera, Melba Trivera Clavell, Melissa T Roy, Michael R Klapal, Michael Serrano, Mindy M Chou, Nancy F Scheraga, Nancy L Rolli, Nancy M Espinal, Natasha Gupta, Nerizza B Guerin, Nicholas A Violand, Niketa Patel, Paul L Bellamy, Paula J Bretz, Randa Melhem, PhD, Regina T Brown, Richard D Manney, Robert D Tollefsen, Robin P Mathew, Rochelle L Cross, Rosario D'costa, Russell J Glapion, Sachinkumar V Patel, Saleem A Akhtar, Sarah Adella Fave, Schultz, Sherri J Liu, Sinai Davis, Stephen J Mottola, Steven Oh, PhD, Susan M Halsted, Tamil Arasu, PhD, Tara G Bizjak, Tara R Gooen, Thomas Finn, PhD, Tonia F Bernard, Unnee Ranjan, Valerie C Reed, William Chang, William R Chang, Xiaohan Cai, PhD, Yvesna C Blaise, Yvins Dezan, Zakaria I Ganiyu, Zhongren Wu

Barbara J Wilimczyk's Documents

Publish Date Document Type Title
January, 2012 EIR Actavis Elizabeth LLC - EIR, 2012-01-13
October, 2013 EIR Hikma Pharmaceuticals USA Inc. - EIR, 2013-10-22
April, 2010 FDA 483 Vantage Specialty Ingredients, Inc - Form 483, 2010-04-08
January, 2010 EIR Dendreon Corporation - EIR, 2010-01-29
November, 2011 FDA 483 Medicia Holdings LLC - Form 483, 2011-11-04
August, 2011 FDA 483 Vitaquest International LLC d/b/a State Nutritionals, Inc. - Form 483, 2011-08-31
October, 2011 FDA 483 Vantage Specialty Ingredients, Inc - Form 483, 2011-10-11
October, 2011 EIR Vantage Specialty Ingredients, Inc - EIR, 2011-10-11
October, 2013 FDA 483 Hikma Pharmaceuticals USA Inc. - Form 483, 2013-10-22
August, 2010 FDA 483 Loricon Testing Service, Inc. - Form 483, 2010-08-12
November, 2010 FDA 483 H & P Industries, Inc. - Form 483, 2010-11-10
July, 2009 FDA 483 Ingenus Pharmaceuticals NJ, LLC - Form 483, 2009-07-07
October, 2009 EIR Akorn Operating Company LLC (dba Akorn) - EIR, 2009-10-06
January, 2010 FDA 483 Dendreon Corporation - Form 483, 2010-01-29
December, 2010 FDA 483 Sunrise Pharmaceutical Inc - Form 483, 2010-12-20
May, 2010 FDA 483 Cosette Pharmaceuticals, Inc. - Form 483, 2010-05-17
January, 2012 FDA 483 Actavis Elizabeth LLC - Form 483, 2012-01-13
June, 2011 FDA 483 Biochem Laboratory, Inc - Form 483, 2011-06-15
January, 2010 FDA 483 Dendreon Corporation - Form 483, 2010-01-29
March, 2011 FDA 483 June Jacobs Labs, LLC - Form 483, 2011-03-21
June, 2010 FDA 483 Rutherford Chemicals, LLC - Form 483, 2010-06-04
September, 2010 FDA 483 Kobo Products, Inc - Form 483, 2010-09-30
June, 2010 FDA 483 Packaging Systems, LLC - Form 483, 2010-06-23

Experience Redica System's NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more